Albert PicadoIsrael CruzMaël Redard-JacotAlejandro G. SchijmanFaustino TorricoSergio Sosa‐EstániZachary KatzJoseph Mathu Ndung’u2026-03-222026-03-22201810.1136/bmjgh-2018-001069https://doi.org/10.1136/bmjgh-2018-001069https://andeanlibrary.org/handle/123456789/44407Citaciones: 68It is estimated that between 8000 and 15 000 <i>Trypanosoma cruzi</i> infected babies are born every year to infected mothers in Chagas disease endemic countries. Currently, poor access to and performance of the current diagnostic algorithm, based on microscopy at birth and serology at 8-12 months after delivery, is one of the barriers to congenital Chagas disease (CCD) control. Detection of parasite DNA using molecular diagnostic tools could be an alternative or complement to current diagnostic methods, but its implementation in endemic regions remains limited. Prompt diagnosis and treatment of CCD cases would have a positive clinical and epidemiological impact. In this paper, we analysed the burden of CCD in Latin America, and the potential use of molecular tests to improve access to early diagnosis and treatment of <i>T. cruzi</i> infected newborns.enChagas diseaseTrypanosoma cruziLatin AmericansEpidemiologySerologyParasitemiaDiseaseMedicinePediatricsDiagnostic testarticle